Serum and urinary concentrations of calprotectin as markers of insulin resistance and type 2 diabetes

European Journal of Endocrinology

Volumn 167, Issue 4, 2012, Pages 569-578

  Ortega, Francisco J ^a   Sabater, Mónica ^a   Moreno Navarrete, José M ^a   Pueyo, Neus ^a   Botas, Patricia ^b   Delgado, Elias ^b   Ricart, Wifredo ^a   Frühbeck, Gema ^c   Fernández Real, José Manuel ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c Instituto de Salud Carlos III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; GLUCOSE;

ADULT; AGE; ARTICLE; BODY MASS; CHRONIC INFLAMMATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIPID METABOLISM; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; WEIGHT REDUCTION;

ADULT; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIET, REDUCING; FEMALE; HUMANS; INSULIN RESISTANCE; LEUKOCYTE L1 ANTIGEN COMPLEX; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OBESITY; OSMOLAR CONCENTRATION; WEIGHT LOSS;

EID: 84866712354     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0374     Document Type: Article

References (31)

1. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006 444 860-867. (doi:10.1038/nature05485)
2. Shoelson SE, Lee J & Goldfine AB. Inflammation and insulin resistance. Journal of Clinical Investigation 2006 116 1793-1801. (doi:10.1172/JCI29069)
3. Fernandez-Real JM & Pickup JC. Innate immunity, insulin resistance and type 2 diabetes. Trends in Endocrinology and Metabolism 2008 19 10-16. (doi:10.1016/j.tem.2007.10.004)
4. Gubern C, Lopez-Bermejo A, Biarnes J, Vendrell J, Ricart W & Fernandez-Real JM. Natural antibiotics and insulin sensitivity: the role of bactericidal/permeability-increasing protein. Diabetes 2006 55 216-224. (doi:10.2337/diabetes.55.01.06.db05-1108)
5. Lopez-Bermejo A, Chico-Julia B, Castro A, Recasens M, Esteve E, Biarnes J, Casamitjana R, Ricart W & Fernandez-Real JM. Alpha defensins 1, 2, and 3: potential roles in dyslipidemia and vascular dysfunction in humans. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 1166-1171. (doi:10.1161/ATVBAHA.106.138594)
6. Moreno-Navarrete JM, Martinez-Barricarte R, Catalan V, Sabater M, Gomez-Ambrosi J, Ortega FJ, Ricart W, Bluher M, Fruhbeck G, Rodriguez de Cordoba S & Fernandez-Real JM. Complement factor H is expressed in adipose tissue in association with insulin resistance. Diabetes 2010 59 200-209. (doi:10.2337/db09-0700)
7. Moreno-Navarrete JM, Ortega FJ, Bassols J, Castro A, Ricart W & Fernandez-Real JM. Association of circulating lactoferrin concentration and 2 nonsynonymous LTF gene polymorphisms with dyslipidemia in men depends on glucose-tolerance status. Clinical Chemistry 2008 54 301-309. (doi:10.1373/clinchem.2007.095943)
8. Striz I & Trebichavsky I. Calprotectin - a pleiotropic molecule in acute and chronic inflammation. Physiological Research 2004 53 245-253.
9. Manitz MP, Horst B, Seeliger S, Strey A, Skryabin BV, Gunzer M, Frings W, Schonlau F, Roth J, Sorg C & Nacken W. Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. Molecular and Cellular Biology 2003 23 1034-1043. (doi:10.1128/MCB.23.3. 1034-1043.2003)
10. Guignard F, Mauel J & Markert M. Phosphorylation of myeloidrelated proteins MRP-14 and MRP-8 during human neutrophil activation. European Journal of Biochemistry 1996 241 265-271. (doi:10.1111/j.1432-1033.1996.0265t.x)
11. Kligman D & Hilt DC. The S100 protein family. Trends in Biochemical Sciences 1988 13 437-443. (doi:10.1016/0968-0004(88)90218-6)
12. Leclerc E, Fritz G, Vetter SW & Heizmann CW. Binding of S100 proteins to RAGE: an update. Biochimica et Biophysica Acta 2009 1793 993-1007. (doi:10.1016/j.bbamcr.2008.11.016)
13. Ehlermann P, Eggers K, Bierhaus A, Most P, Weichenhan D, Greten J, Nawroth PP, Katus HA & Remppis A. Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovascular Diabetology 2006 5 6. (doi:10.1186/1475-2840-5-6)
14. Foell D & Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis and Rheumatism 2004 50 3762-3771. (doi:10.1002/art.20631)
15. Leach ST, Mitchell HM, Geczy CL, Sherman PM & Day AS. S100 calgranulin proteins S100A8, S100A9 and S100A12 are expressed in the inflamed gastric mucosa of Helicobacter pylori-infected children. Canadian Journal of Gastroenterology 2008 22 461-464.
16. Leach ST, Yang Z, Messina I, Song C, Geczy CL, Cunningham AM & Day AS. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scandinavian Journal of Gasteroenterology 2007 42 1321-1331. (doi:10.1080/00365520701416709)
17. Mortensen OH, Nielsen AR, Erikstrup C, Plomgaard P, Fischer CP, Krogh-Madsen R, Lindegaard B, Petersen AM, Taudorf S & Pedersen BK. Calprotectin - a novel marker of obesity. PLoS ONE 2009 4 e7419. (doi:10.1371/journal.pone.0007419)
18. Nijhuis J, Rensen SS, Slaats Y, van Dielen FM, Buurman WA & Greve JW. Neutrophil activation in morbid obesity, chronic activation of acute inflammation. Obesity 2009 17 2014-2018. (doi:10.1038/oby.2009.113)
19. Matheson A, Willcox MD, Flanagan J & Walsh BJ. Urinary biomarkers involved in type 2 diabetes: a review. Diabetes/Metabolism Research and Reviews 2010 26 150-171. (doi:10.1002/dmrr.1068)
20. Valdes S, Botas P, Delgado E, Alvarez F & Cadorniga FD. Population-based incidence of type 2 diabetes in northern Spain: the Asturias Study. Diabetes Care 2007 30 2258-2263. (doi:10.2337/dc06-2461)
21. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T & Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000 23 57-63. (doi:10.2337/diacare.23.1.57)
22. Bergman RN, Prager R, Volund A & Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. Journal of Clinical Investigation 1987 79 790-800. (doi:10.1172/JCI112886)
23. Lopez-Bermejo A, Ortega FJ, Castro A, Ricart W & Fernandez-Real JM. The alarm secretory leukocyte protease inhibitor increases with progressive metabolic dysfunction. Clinica Chimica Acta 2011 412 1122-1126. (doi:10.1016/j.cca.2011.02.037)
24. Vogl T, Leukert N, Barczyk K, Strupat K & Roth J. Biophysical characterization of S100A8 and S100A9 in the absence and presence of bivalent cations. Biochimica et Biophysica Acta 2006 1763 1298-1306. (doi:10.1016/j. bbamcr.2006.08.028)
25. Foell D, Hernandez-Rodriguez J, Sanchez M, Vogl T, Cid MC & Roth J. Early recruitment of phagocytes contributes to the vascular inflammation of giant cell arteritis. Journal of Pathology 2004 204 311-316. (doi:10.1002/path.1660)
26. Halayko AJ & Ghavami S. S100A8/A9: a mediator of severe asthma pathogenesis and morbidity? Canadian Journal of Physiology and Pharmacology 2009 87 743-755. (doi:10.1139/Y09-054)
27. Gregor MF & Hotamisligil GS. Inflammatory mechanisms in obesity. Annual Review of Immunology 2011 29 415-445. (doi:10.1146/annurev-immunol- 031210-101322)
28. Wellen KE & Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. Journal of Clinical Investigation 2003 112 1785-1788. (doi:10.1172/JCI20514)
29. Navarro JF & Mora C. Perspectives and usefulness of inflammatory biomarkers within the context of chronic renal disease. Nefrologia 2007 27 (Suppl 6) 8-14.
30. Fernandez-Real JM, Lopez-Bermejo A, Castro A, Broch M, Penarroja G, Vendrell J, Vazquez G & Ricart W. Opposite relationship between circulating soluble CD14 concentration and endothelial function in diabetic and nondiabetic subjects. Thrombosis and Haemostasis 2005 94 615-619. (doi:10.1160/TH05-03-0615)
31. Sun L, Yu Z, Ye X, Zou S, Li H, Yu D, Wu H, Chen Y, Dore J, Clement K, Hu FB & Lin X. A marker of endotoxemia is associated with obesity and related metabolic disorders in apparently healthy Chinese. Diabetes Care2010331925-1932. (doi:10.2337/dc10-0340)